Neurelis Announces FDA Approval for Seizure Rescue Treatment VALTOCO® (Diazepam Nasal Spray) that Incorporates the Science of Intravail® for Consistent and Reliable Absorption

-- VALTOCO (diazepam nasal spray) is approved by the U.S. Food and Drug Administration (FDA) for use by a care partner outside of the medical setting for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern

-- VALTOCO is the first nasal spray approved by the FDA as a rescue treatment for people with epilepsy aged 6 and older

-- VALTOCO's proprietary formulation including Intravail® has been shown to be generally safe and well tolerated

-- VALTOCO granted Orphan Drug Exclusivity by the FDA

NeoGenomics Acquires Oncology Division from Human Longevity for $37 Million

Significantly Enhances Next Generation Sequencing Capabilities for Pharmaceutical Customers

晨泰医药在研药品Zorifertinib专家顾问会议在沪召开

2020年1月3日，晨泰医药科技有限公司主导在研产品（AZD3759）的化学名Zorifertinib及该研究命名仪式日前在上海隆重举行。

Qpex was selected to be among Top Life Science Companies to Watch in 2020

BioSpace is present its NextGen Bio “Class of 2020,” a list of up-and-coming life sciences companies in North America that launched* no earlier than mid-2018.

Qpex Biopharma Announces Exercise of $20 Million Option by BARDA under its Other Transaction Authority (OTA) Agreement to Advance Multiple Products into Clinical Studies

Qpex Biopharma, Inc., a biopharmaceutical company dedicated to the discovery and development of innovative anti-infective therapies, today announced that the Biomedical Advanced Research and Development Authority (BARDA) has exercised its first agreement option, which will support advancing multiple programs into clinical studies.

IQVIA与SocialMED达成独家战略合作 智能营销全方位升维

10月31日，IQVIA宣布与醴泽资本旗下的SocialMED（下称“智云”）达成独家战略合作，共建基于人工智能的远程数字化营销服务解决方案，成立中国数字化销售代表运营中心，联动线上线下渠道，将数据和算法真正转化为商业创新和实践，共同推动数字化精准营销升维，释放数字智慧医疗价值。